摩洛哥患者冠状动脉静脉静脉阻塞的危险因素:一个回顾性病例控制研究
Rajaa El Mansouri1, Rachida Habbal2
1Medical School, Laboratory of Genetics and Molecular Pathology, University Hassan II, Casablanca, Morocco. rajaa.elmansouri-etu@etu.univh2c.ma.
Cellular and molecular biology (Noisy-le-Grand, France)
|September 8, 2025
概括
糖尿病显著增加了冠状动脉干预后静脉支架缩的风险. 控制血糖和脂质对于预防糖尿病患者的静止症至关重要.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 血管生物学 血管生物学
背景情况:
- 干预性心脏病学中,静脉静脉缩 (ISR) 是一个重大的临床挑战.
- 尽管取得了进展,但对ISR的特定风险因素的识别仍然对患者的治疗结果至关重要.
研究的目的:
- 调查与冠状动脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉.
- 评估糖尿病和脂质特征在ISR发展中的作用.
主要方法:
- 追溯病例对照研究涉及68名患者 (静脉缩与非静脉缩组).
- 分析临床数据,包括糖尿病状况,脂质概况,药物持续时间和支架特征.
- 统变逻辑回归用于确定复原症的显著预测因子.
主要成果:
- 糖尿病是一种强有力的预测器的静止 (RR=4.15).
- 静止病患者的LDL胆固醇显著增加,HDL胆固醇水平降低.
- 药物服用时间 (OR=1.30) 和LDL水平 (OR=26.7) 是重要的因素.
结论:
- 糖尿病是冠状动脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉.
- 糖尿病和脂质异常的协同效应有助于ISR.
- 针对性预防策略,包括血糖和脂质管理,对于接受PCI的糖尿病患者至关重要.
更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
4.2K
05:04Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access
Published on: November 19, 2020
4.7K
相关概念视频
01:30Coronary Artery Disease I: Introduction
843
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
843
01:26Coronary Artery Disease IV: Preventive Measures
563
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
563
01:27Coronary Artery Disease V: Interprofessional Care
202
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
202
01:30Coronary Artery Disease III: Clinical Manifestations
295
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
295
01:26Coronary Artery Disease II: Pathophysiology
332
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
332
01:26Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290